Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 244Melanoma 141Squamous Cell Carcinoma of Head and Neck 139Parkinson Disease 4, Autosomal Dominant Lewy Body 119Neoplasm Metastasis 104Triple Negative Breast Neoplasms 96Neoplasms 91Lung Neoplasms 91Breast Neoplasms 81Colorectal Neoplasms 70Carcinoma, Renal Cell 69Head and Neck Neoplasms 59Urinary Bladder Neoplasms 50Stomach Neoplasms 47Ovarian Neoplasms 46Endometrial Neoplasms 46Carcinoma, Transitional Cell 44Carcinoma, Hepatocellular 35Uterine Cervical Neoplasms 34Pancreatic Neoplasms 34Esophageal Neoplasms 27Prostatic Neoplasms 26Recurrence 25Carcinoma, Squamous Cell 25Carcinoma 25Sarcoma 24Brain Neoplasms 24Glioblastoma 23Hodgkin Disease 19Cholangiocarcinoma 19

Interventions

Cisplatin 2pembrolizumab 1cediranib 1Vinorelbine 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Platinum 1Pharmacogenomic Testing 1Pemetrexed 1Neoadjuvant Therapy 1Methotrexate 1Chemotherapy, Adjuvant 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solitary Fibrous Tumor, Pleural × pembrolizumab × 1 year × Clear all
NCT02399371 2026-05-08

Pembrolizumab in Treating Patients With Malignant Mesothelioma

University of Chicago

Phase 2 Completed
65 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡